These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

353 related articles for article (PubMed ID: 27423416)

  • 41. New pharmacokinetic/pharmacodynamic studies of systemically administered colistin against Pseudomonas aeruginosa and Acinetobacter baumannii in mouse thigh and lung infection models: smaller response in lung infection.
    Cheah SE; Wang J; Nguyen VT; Turnidge JD; Li J; Nation RL
    J Antimicrob Chemother; 2015 Dec; 70(12):3291-7. PubMed ID: 26318190
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Nebulized colistin treatment of multi-resistant Acinetobacter baumannii pulmonary infection in critical ill patients].
    Pérez-Pedrero MJ; Sánchez-Casado M; Rodríguez-Villar S
    Med Intensiva; 2011 May; 35(4):226-31. PubMed ID: 21396739
    [TBL] [Abstract][Full Text] [Related]  

  • 43. In vitro activities of rifampin, colistin, sulbactam and tigecycline tested alone and in combination against extensively drug-resistant Acinetobacter baumannii.
    Dong X; Chen F; Zhang Y; Liu H; Liu Y; Ma L
    J Antibiot (Tokyo); 2014 Sep; 67(9):677-80. PubMed ID: 25095805
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Risk factors of mortality in patients with carbapenem-resistant Acinetobacter baumannii bacteremia.
    Liu CP; Shih SC; Wang NY; Wu AY; Sun FJ; Chow SF; Chen TL; Yan TR
    J Microbiol Immunol Infect; 2016 Dec; 49(6):934-940. PubMed ID: 25553994
    [TBL] [Abstract][Full Text] [Related]  

  • 45. fAUC/MIC is the most predictive pharmacokinetic/pharmacodynamic index of colistin against Acinetobacter baumannii in murine thigh and lung infection models.
    Dudhani RV; Turnidge JD; Nation RL; Li J
    J Antimicrob Chemother; 2010 Sep; 65(9):1984-90. PubMed ID: 20573659
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Differences in pharmacokinetics and pharmacodynamics of colistimethate sodium (CMS) and colistin between three different CMS dosage regimens in a critically ill patient infected by a multidrug-resistant Acinetobacter baumannii.
    Luque S; Grau S; Valle M; Sorlí L; Horcajada JP; Segura C; Alvarez-Lerma F
    Int J Antimicrob Agents; 2013 Aug; 42(2):178-81. PubMed ID: 23769664
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Comparison of pneumonia- and non-pneumonia-related Acinetobacter baumannii bacteremia: Impact on empiric therapy and antibiotic resistance.
    Teng SO; Yen MY; Ou TY; Chen FL; Yu FL; Lee WS
    J Microbiol Immunol Infect; 2015 Oct; 48(5):525-30. PubMed ID: 25103719
    [TBL] [Abstract][Full Text] [Related]  

  • 48. In Vivo Selection of Pan-Drug Resistant Acinetobacter baumannii during Antibiotic Treatment.
    Kim Y; Bae IK; Jeong SH; Yong D; Lee K
    Yonsei Med J; 2015 Jul; 56(4):928-34. PubMed ID: 26069113
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Colistin for pneumonia involving multidrug-resistant Acinetobacter calcoaceticus-Acinetobacter baumannii complex.
    Zheng JY; Huang SS; Huang SH; Ye JJ
    J Microbiol Immunol Infect; 2020 Dec; 53(6):854-865. PubMed ID: 31607573
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Comparative assessment of antimicrobial susceptibility testing for tigecycline and colistin against Acinetobacter baumannii clinical isolates, including multidrug-resistant isolates.
    Piewngam P; Kiratisin P
    Int J Antimicrob Agents; 2014 Nov; 44(5):396-401. PubMed ID: 25442358
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Extensively drug-resistant Acinetobacter baumannii bacteraemia in a multidisciplinary intensive care unit during a 6-year period: Risk factors for fulminant sepsis.
    Katsiari M; Mavroidi A; Platsouka ED; Nikolaou C
    J Glob Antimicrob Resist; 2018 Sep; 14():51-57. PubMed ID: 29471109
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Emergence of colistin resistance without loss of fitness and virulence after prolonged colistin administration in a patient with extensively drug-resistant Acinetobacter baumannii.
    Durante-Mangoni E; Del Franco M; Andini R; Bernardo M; Giannouli M; Zarrilli R
    Diagn Microbiol Infect Dis; 2015 Jul; 82(3):222-6. PubMed ID: 25858028
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Colistin-tigecycline versus colistin-imipenem-cilastatin combinations for the treatment of Acinetobacter baumannii ventilator-acquired pneumonia: a prognosis study.
    Chaari A; Pham T; Mnif B; Chtara K; Medhioub F; Baccouche N; Bahloul M; Hammami A; Bouaziz M
    Intensive Care Med; 2015 Nov; 41(11):2018-9. PubMed ID: 26264246
    [No Abstract]   [Full Text] [Related]  

  • 54. In vitro activities of colistin and ampicillin/sulbactam against Acinetobacter baumannii.
    Punpanich W; Munsrichoom A; Srisarang S; Treeratweeraphong V
    J Med Assoc Thai; 2011 Aug; 94 Suppl 3():S95-100. PubMed ID: 22043760
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Efficacy and safety of high-dose ampicillin/sulbactam vs. colistin as monotherapy for the treatment of multidrug resistant Acinetobacter baumannii ventilator-associated pneumonia.
    Betrosian AP; Frantzeskaki F; Xanthaki A; Douzinas EE
    J Infect; 2008 Jun; 56(6):432-6. PubMed ID: 18501431
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Epidemiology, clinical characteristics and outcomes of extensively drug-resistant Acinetobacter baumannii infections among solid organ transplant recipients.
    Shields RK; Clancy CJ; Gillis LM; Kwak EJ; Silveira FP; Massih RC; Eschenauer GA; Potoski BA; Nguyen MH
    PLoS One; 2012; 7(12):e52349. PubMed ID: 23285002
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Retrospective evaluation of colistin versus tigecycline for the treatment of Acinetobacter baumannii and/or carbapenem-resistant Enterobacteriaceae infections.
    Ku K; Pogue JM; Moshos J; Bheemreddy S; Wang Y; Bhargava A; Campbell M; Khandker N; Lephart PR; Chopra T; Hayakawa K; Martin ET; Abreu-Lanfranco O; Dhar S; Kaye KS; Marchaim D
    Am J Infect Control; 2012 Dec; 40(10):983-7. PubMed ID: 22440526
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Colistin hetero-resistance in multidrug-resistant Acinetobacter baumannii clinical isolates from the Western Pacific region in the SENTRY antimicrobial surveillance programme.
    Yau W; Owen RJ; Poudyal A; Bell JM; Turnidge JD; Yu HH; Nation RL; Li J
    J Infect; 2009 Feb; 58(2):138-44. PubMed ID: 19058855
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Treatment of multidrug-resistant Acinetobacter baumannii ventilator-associated pneumonia (VAP) with intravenous colistin: a comparison with imipenem-susceptible VAP.
    Garnacho-Montero J; Ortiz-Leyba C; Jiménez-Jiménez FJ; Barrero-Almodóvar AE; García-Garmendia JL; Bernabeu-WittelI M; Gallego-Lara SL; Madrazo-Osuna J
    Clin Infect Dis; 2003 May; 36(9):1111-8. PubMed ID: 12715304
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Comparison of colistin and colistin/sulbactam for the treatment of multidrug resistant Acinetobacter baumannii ventilator-associated pneumonia.
    Kalin G; Alp E; Akin A; Coskun R; Doganay M
    Infection; 2014 Feb; 42(1):37-42. PubMed ID: 23828559
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.